DOWNINGTOWN, Pa. (Jan. 4, 2020) -- ValSource, Inc, a consulting and advisory service provider for the regulated biological, medical device, and pharmaceutical industries, today announced a new corporate identity, including logo redesign and messaging refinement, as well as the launch of a new website. The refreshed brand and digital presence complement ValSource’s legacy as pioneers in the regulated industry while providing current and future clients a complete overview of core services and processes. “ValSource’s brand evolution resulted in a more refined, effective corporate identity and web presence that better communicates the breadth of expertise ValSource represents,” said Whitney Kutney, ValSource vice president. Equipped with a new logo, tagline, mission, and vision, ValSource’s updated brand messaging and detailed expansion of services unifies the corporate team - providing renewed purpose and direction in their efforts to support clients in need of compliance and advisory services. To bring the updated verbal and visual identity to life, a new user-friendly, information-rich website was built with client needs first. Explore the new ValSource website at www.valsource.com. The new identity and website were created and launched by Tayloe/Gray, ValSource’s agency of record. Tayloe/Gray is a full-service digital marketing agency skilled in impactful branding, design, and web development. “It’s been a pleasure to work with Tayloe/Gray throughout the rebranding process. Although our brand is evolving, our commitment to our clients and our employees remains the same. We are looking forward to a fresh start to 2021,” said Kutney.

DOWNINGTOWN, Pa. (Nov. 16, 2020) — ValSource, Inc, a consulting and advisory service provider for the regulated biological, medical device, and pharmaceutical industries, today announced the addition of three new directors to the corporate board. The new ValSource directors include Diane Blumenthal, Katherine Oates, and Robert Radie, each bringing a diverse skill set to the leadership team.

Diane Blumenthal joins the ValSource board of directors with more than 35 years of experience in biopharmaceutical process and product development, clinical and commercial manufacturing, quality control, scientific facilities, program management, and CMC regulatory. Former SVP/Head of Technical Operations at Spark Therapeutics, Ms. Blumenthal is skilled in building and transitioning companies from a start-up research and development organization to a fully integrated biopharmaceutical company with approved commercial manufacturing operations and products. Throughout her career, Ms. Blumenthal has played a key role in the development and commercialization of several well-known pharmaceutical products.

Katherine Oates brings over 25 years of human resources executive experience to the board of directors at ValSource. Ms. Oates is currently the VP of Human Resources for GlaxoSmithKline’s US Pharmaceuticals business. Throughout Ms. Oates’ career with GSK, she has worked with multiple businesses in a variety of HR leadership roles. Ms. Oates’ primary focus throughout her career has been enhancing organizational effectiveness through talent management, workforce engagement, leadership development, and culture.

Robert Radie joins the ValSource board of directors with three decades of experience working in both public and private pharmaceutical and biotech companies, and across a range of therapeutic areas. Mr. Radie is currently the Chairman of the Board and CEO at Neuraptive Therapeutics, he has also held senior executive positions in six companies, including serving as Chief Executive Officer of Zyla Life Sciences, Inc. Transmolecular Inc, and Topaz Pharmaceuticals, Inc., which was acquired by Sanofi Pasteur. Mr. Radie also currently serves on the board of directors of several companies, including Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK), and Rockwell Medical Technologies Inc. (NASDAQ: RMTI).

The appointment of Ms. Blumenthal, Ms. Oates, and Mr. Radie to the Board of Directors provide the ValSource executive team access to a diverse group of backgrounds, skills, and experience from the life science fields. Our Board of Directors is committed to the success of ValSource. We are excited to leverage their talent and expertise to further our mission.

About ValSource

ValSource is the premier provider of consulting and advisory services for the biological, medical device, and pharmaceutical industries. The company specializes in program and project delivery including capital project execution, procurement, commissioning, qualification and validation, compliance, and quality risk management – serving clients as advisors, trusted consultants, and highly experienced program managers. Valsource is committed to helping projects get to a qualified and validated state with the most efficient solutions. To learn more, visit our website and follow us on LinkedIn and Facebook.

CONTACT: ValSource, Inc Whitney Kutney, Vice President wkutney@valsource.com

Senior Microbiology Consultant Stephen Langille was recently elected to the United States Pharmacopeia’s Compounding Expert Committee for the 2020-2025 cycle. The USP Council of Experts and its Expert Committees are responsible for developing and revising standards for medicines and foods that appear in USP’s compendia, including the United States Pharmacopeia and the National Formulary (USP–NF), which contains quality standards for drug ingredients, drug products, and dietary supplements; the Food Chemicals Codex (FCC); the Dietary Supplements Compendium (DSC); and in other related publications. They also approve USP Reference Standards specified for use in the compendia. Members of the Council of Experts and its Expert Committees develop and review monographs, General Chapters, and testing methods, and collaborate on scientific topics supporting the standards that appear in USP's compendia. Stephen Langille, Ph.D., is a senior microbiology consultant at ValSource, Inc. He specializes in microbiological and particulate matter contamination control. He holds a B.S. degree in biology from the University of Massachusetts and a Ph.D. in microbiology from the University of Maryland. He spent 19 years with the FDA as a microbiology reviewer, branch chief, and director of the Division of Microbiology Assessment in the Center for Drug Evaluation and Research.